|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
Improved knowledge of the immune/inflammatory pathways, which characterise the pathophysiology of rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA), such as ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have provided the link between inflammation and bone loss, via a complex network of bone cells, T and B cells, pro-inflammatory cytokines such as TNF-α, IL1, IL6, IL17, IL23, costimulator molecules, signalling pathways including both RANKL/RANK/OPG and Wnt signallings.
|
30557124 |
2019 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study.
|
31335881 |
2019 |
|
Spondylarthropathies
|
0.300 |
GeneticVariation
|
group |
BEFREE |
To determine the incidence of serious infections (SIs) among the spondyloarthropathy (SpA) patients from the "Gruppo Italiano per lo Studio delle Early Arthritis" (GISEA) registry and treated with tumour necrosis factor (TNF) inhibitors (TNFIs), and to identify the factors associated with the development of the infections.
|
30767865 |
2019 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
The efficacy and tolerability of biological agents, from the initial tumour necrosis factor (TNF)-α inhibitors to the new anti-cytokine monoclonal antibodies, have dramatically changed the natural history of debilitating conditions such as rheumatoid arthritis and seronegative spondyloarthropathies.
|
30971924 |
2019 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
The management of SpA has dramatically improved over the last decades due to the development of new treat-to-target strategies and to the introduction of biologic disease modifying antirheumatic drugs (bDMARDs), particularly tumor necrosis factor alpha inhibitors (TNFis), currently used for the treatment of nonresponder patients to conventional synthetic agents.
|
30406148 |
2018 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
MGD |
Mesenchymal TNFR2 promotes the development of polyarthritis and comorbid heart valve stenosis.
|
29618659 |
2018 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
107 TNF-inhibitor treated stable ax-SpA patients were identified in the Danish rheumatology registry (DANBIO).
|
29299630 |
2018 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor alpha (TNF alpha) antagonists are biologic agents used in the management of inflammatory conditions such as rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory bowel disease.
|
27748629 |
2017 |
|
Spondylarthropathies
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.
|
27490376 |
2016 |
|
Spondylarthropathies
|
0.300 |
GeneticVariation
|
group |
BEFREE |
Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.
|
26244882 |
2015 |
|
Spondylarthropathies
|
0.300 |
GeneticVariation
|
group |
BEFREE |
CD14 and TNfa promoter polymorphisms in patients with acute arthritis. Special reference to development of chronic spondyloarthropathy.
|
12492251 |
2002 |
|
Spondylarthropathies
|
0.300 |
Biomarker
|
group |
MGD |
Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease.
|
12486099 |
2002 |
|
Spondylarthropathies
|
0.300 |
AlteredExpression
|
group |
BEFREE |
The repertoires of proinflammatory cytokines/chemokines expressed by SpA and RA SFMC were very similar: monocyte chemotractant protein 1 (MCP-1), interleukin 8 (IL-8), IL-1beta, endothelial-monocyte activating polypeptide II, interferon-gamma, and tumor necrosis factor-alpha.MCP-1 was highly expressed in SpA SFMC.
|
12375327 |
2002 |
|
Spondylarthropathies
|
0.300 |
AlteredExpression
|
group |
BEFREE |
05); there were also higher synovial fluid levels of tumour necrosis factor alpha in RA than in SpA, but without statistical significance.
|
10733472 |
2000 |